Regeneus reported that its STEP Phase I trial of Progenza in patients with knee osteoarthritis has completed recruitment and that a review of safety data did not identify any safety concerns. The study will complete in H117 when all patients have completed 12 months follow-up. We believe the positive safety review augurs well for the company’s plan to secure a manufacturing and commercial partner for its Progenza mesenchymal stem cell therapy technology in Japan in the current quarter,
19 May 2016
Potential Japan licence deal a STEP closer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Potential Japan licence deal a STEP closer
Cambium Bio Ltd (CMB:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
19 May 2016 -
Author:
Dr Dennis Hulme -
Pages:
7
Regeneus reported that its STEP Phase I trial of Progenza in patients with knee osteoarthritis has completed recruitment and that a review of safety data did not identify any safety concerns. The study will complete in H117 when all patients have completed 12 months follow-up. We believe the positive safety review augurs well for the company’s plan to secure a manufacturing and commercial partner for its Progenza mesenchymal stem cell therapy technology in Japan in the current quarter,